



This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Induced pluripotent stem (iPS) cell–derived pancreatic β -like cells for treating diabetes	Studies in mice suggest that iPS cell–derived pancreatic β -like cells could help treat type 1 and type 2 diabetes. In a mouse model of type 2 diabetes, a transplant containing about 200,000 iPS cell–derived pancreatic β -like cells engrafted in the liver. The animals with engrafted cells achieved normal glycemic control, whereas animals given control cells or no cells remained hyperglycemic. In a mouse model of type 1 diabetes, transplantation of the pancreatic β -like cells restored normal glycemic control after two days compared with no transplantation. Next steps include evaluating the cell therapy in large animal models of diabetes and developing protocols to generate clinical-grade iPS cell–derived β -like cells. SciBX 3(28); doi:10.1038/scibx.2010.879 Published online July 22, 2010	Patent application filed; licensing inquiries should be directed to corresponding authors	Alipio, Z. et al. Proc. Natl. Acad. Sci. USA; published online July 6, 2010; doi:10.1073/pnas.1007884107 Contact: Yupo Ma, State University of New York at Stony Brook, Stony Brook, N.Y. e-mail: yupo.ma@stonybrook.edu Contact: David C. Ward, University of Hawaii, Honolulu, Hawaii e-mail: dward@crch.hawaii.edu